Binding site
I1 imidazoline site
Imidazoline-1 receptor / binding site
- GeneNISCH
- FamilyImidazoline receptors
According to a review, second-generation centrally acting antihypertensives inhibit sympathetic activity mainly through imidazoline receptors, whereas first-generation agents act through α2-adrenergic receptors. The I1 subtype resides in the plasma membrane and binds central antihypertensives with high affinity. Binding affinity at I1 sites, but not at other classes of imidazoline binding sites, correlates closely with the potency of central antihypertensive agents in animals and in clinical trials. The antihypertensive action of systemic moxonidine is eliminated by the I1/α2 antagonist efaroxan, but not by selective blockade of α2-adrenergic receptors.1
Sources (1)
- Ernsberger et al. 1997Ernsberger P, Friedman JE, Koletsky RJ (1997) The I1-imidazoline receptor: from binding site to therapeutic target in cardiovascular disease J Hypertens Suppl
Binding affinity (Kᵢ)
8 substances, 8 displayed values. Strongest first within each organism. The bar is pKᵢ on a log scale. Open a row to see the assay and every report behind the value.
Human
8 measurements
5-MeO-MiPT879 nMRay 2010
- Assay
- PDSP receptorome (compiled; species not stated per entry, predominantly human clones)
- Shown value from
- Ray 2010, Table S2 (AllKiData)
Values are published numbers in nM per organism. Different assays, species and receptor preparations are not directly interchangeable, and a value does not establish clinical potency or safety.